A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients
Main Authors: | Pavel, M, Schuppan, D, Jost, L, Kerr, D, Harris, A, Jalava, T, Masson, E, Palacay-Radona, M, Koehne, C |
---|---|
Format: | Journal article |
Published: |
2005
|
Similar Items
-
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
by: Giatromanolaki, A, et al.
Published: (2012) -
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
by: Koukourakis, M, et al.
Published: (2011) -
Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis
by: Marlies H.G. Langenberg, et al.
Published: (2010-02-01) -
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
by: Hecht, JR, et al.
Published: (2011) -
A phase II study of PTK787 in metastatic melanoma patients
by: Corrie, P, et al.
Published: (2008)